top of page

On Demand Meeting

|

Book your online meeting with our team

Illumina COVIDSeq

The Illumina COVIDSeq Test is the first NGS test approved for use under the U.S. Food and Drug Administration’s Emergency Use Authorization (EUA).

Registration is Closed
See other events
Illumina COVIDSeq
Illumina COVIDSeq

Time & Location

On Demand Meeting

Book your online meeting with our team

About the Event

Rapid, Scalable SARS-CoV-2 Detection

The Illumina COVIDSeq Test can be scaled up or down to accommodate different numbers of samples. 1536 to 3072 results can be processed in 12 hours on NovaSeq 6000 system using two SP or S4 reagent kits, respectively or 384 results in 12 hours using NextSeq 500/550/550Dx (in RUO mode) HO reagent kit.

Workflow and Components

The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. Key components include the high-throughput NovaSeq 6000 System or the NextSeq 500/550/550Dx (in RUO mode) Systems, coupled with the Illumina COVIDSeq Test and the DRAGEN COVIDSeq Test Pipeline or DRAGEN COVIDSeq Test App in BaseSpace Sequence Hub for rapid analysis.

Design and Quality Control

The Illumina COVIDSeq Test leverages a modified version of the validated, publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. As a quality feature, an internal control consisting of 11 human mRNA targets is included in every sample.

Share This Event

bottom of page